Genome-wide gene expression profiles of clear cell renal cell carcinoma: Identification of molecular targets for treatment of renal cell carcinoma

被引:1
作者
Hirota, Eiji
Yan, Liang
Tsunoda, Tatsuhiko
Ashida, Shingo
Fujime, Makoto
Shuin, Taro
Miki, Tsuneharu
Nakamura, Yusuke
Katagiri, Toyomasa
机构
[1] Univ Tokyo, Inst Med Sci, Human Genome Ctr, Lab Mol Med,Minato Ku, Tokyo 1088639, Japan
[2] Kyoto Prefectural Univ Med, Dept Urol, Kyoto 6028566, Japan
[3] RIKEN, SNP Res Ctr, Lab Med Informat, Kanagawa 2300045, Japan
[4] Kochi Med Sch, Dept Urol, Kochi 7838505, Japan
[5] Juntendo Univ, Sch Med, Dept Urol, Tokyo 1138431, Japan
关键词
clear cell renal cell carcinoma; cDNA microarray; laser microbeam microdissection; expression profile;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In order to clarify the molecular mechanism involved in renal carcinogenesis, and to identify molecular targets for diagnosis and treatment, we analyzed genome-wide gene expression profiles of 15 surgical specimens of clear cell renal cell carcinoma (RCC), compared to normal renal cortex, using a combination of laser microbeam microdissection (LMM) with a cDNA microarray representing 27,648 genes. We identified 257 genes that were commonly up-regulated and 721 genes that were down-regulated in RCCs. None of top 24 up-regulated genes that showed most significant differences in informative RCC-cases were included in previous reports describing expression profiles of RCC using RNAs isolated from bulk tissues. These findings suggest that it is important to purify as much as possible the populations of cancerous and normal epithelial cells obtained from surgical specimens. Among the significantly-transactivated genes, we focused on Semaphorin 5B (SEMA5B) and knocked-down its expression in RCC cells by small-interfering RNA (siRNA). Effective down-regulation of its expression levels in RCC cells significantly attenuated RCC cell viability. In conclusion, our data should be helpful for a better understanding of the tumorigenesis of RCC and should contribute to the development of diagnostic tumor markers and molecular-targeting therapy for patients with RCC.
引用
收藏
页码:799 / 827
页数:29
相关论文
共 34 条
[21]   Differential gene expression in renal-cell cancer [J].
Skubitz, KM ;
Skubitz, APN .
JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 2002, 140 (01) :52-64
[22]   Targeted agents for the treatment of advanced renal cell carcinoma [J].
Staehler, M ;
Rohrmann, K ;
Haseke, N ;
Stief, CG ;
Siebels, M .
CURRENT DRUG TARGETS, 2005, 6 (07) :835-846
[23]   Guidelines for the surveillance of localized renal cell carcinoma based on the patterns of relapse after nephrectomy [J].
Stephenson, AJ ;
Chetner, MP ;
Rourke, K ;
Gleave, ME ;
Signaevsky, M ;
Palmer, B ;
Kuan, J ;
Brock, GB ;
Tanguay, S .
JOURNAL OF UROLOGY, 2004, 172 (01) :58-62
[24]  
Storkel S, 1997, CANCER, V80, P987, DOI 10.1002/(SICI)1097-0142(19970901)80:5<987::AID-CNCR24>3.0.CO
[25]  
2-R
[26]  
Takahash M, 2005, INT J ONCOL, V26, P923
[27]   Gene expression profiling of clear cell renal cell carcinoma: Gene identification and prognostic classification [J].
Takahashi, M ;
Rhodes, DR ;
Furge, KA ;
Kanayamat, H ;
Kagawa, S ;
Haab, BB ;
Teh, BT .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (17) :9754-9759
[28]  
Tamagnone L, 2004, EMBO REP, V5, P356, DOI 10.1038/sj.embor.7400114
[29]   Hypoxia-inducible protein 2 (HIG2), a novel diagnostic marker for renal cell carcinoma and potential target for molecular therapy [J].
Togashi, A ;
Katagiri, T ;
Ashida, S ;
Fujioka, T ;
Maruyama, O ;
Wakumoto, Y ;
Sakamoto, Y ;
Fujime, M ;
Kawachi, Y ;
Shuin, T ;
Nakamura, Y .
CANCER RESEARCH, 2005, 65 (11) :4817-4826
[30]   Suppression of cell transformation by the cyclin-dependent kinase inhibitor p57KIP2 requires binding to proliferating cell nuclear antigen [J].
Watanabe, H ;
Pan, ZQ ;
Schreiber-Agus, N ;
DePinho, RA ;
Hurwitz, J ;
Xiong, Y .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (04) :1392-1397